Ribociclib Still Allows Recurrence: HR+/HER2- Adjuvant and Advanced Use

　　1.Not a“No-Metastasis Guarantee”

　　Ribociclib selectively inhibits CDK4/6,blocks cyclin D binding,reduces pRb phosphorylation,and stalls cells in G1.

　　It slows proliferation but does not erase micrometastatic disease.

　　Indication boundary:HR+/HER2-​only.

　　2.Early Breast Cancer

　　Adjuvant ribociclib+AI for stage II–III,higher recurrence risk.

　　NATALEE:

　　400mg daily,3 weeks on/1 week off,up to~3 years;

　　AI continued≥5 years;

　　iDFS improved;

　　distant recurrence risk reduced~28.5%,not eliminated.

　　Typical candidates:

　　node-positive;

　　node-negative but large tumor/high grade/high Ki-67/genomic risk.

　　Not“any HR+”automatically;not HER2+.

　　3.Advanced/Metastatic

　　600mg daily,21 days on/7 off,with AI.

　　Goal:delay progression,extend PFS,preserve quality of life.

　　Premenopausal:add LHRH agonist.

　　If liver/lung/bone progression appears,do not self-escalate dose;switch strategy per oncologist.

　　4.Why Recurrence Still Happens

　　residual micrometastases;

　　CDK4/6-independent clones;

　　endocrine resistance;

　　missed doses/CYP3A interactions;

　　high tumor burden at baseline.

　　5.Safety Monitoring

　　Common:neutropenia,nausea,fatigue,transaminase rise.

　　Monitor:

　　CBC baseline,q2w first 2 cycles;

　　LFTs same schedule;

　　ECG baseline,day 14 cycle 1,cycle 2 start;

　　electrolytes first 6 cycles;

　　avoid strong CYP3A inhibitors/inducers,grapefruit.

　　Hold/reduce if:

　　ANC<1.0×10⁹/L;

　　hepatotoxicity with bilirubin rise;

　　QTc>480ms;

　　febrile neutropenia.

　　6.How to Judge Progression

　　Tumor markers alone are not enough.

　　Use imaging+exam+symptom trend:

　　CT/MRI/bone scan;

　　new lesions;

　　worsening bone pain,dyspnea,persistent headache;

　　regular follow-up even if asymptomatic.